Hoth Therapeutics Files 8-K

TL;DR

HOTH filed an 8-K on Nov 20, 2024, updating corporate info.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on November 20, 2024, reporting other events and financial statements. The filing details the company's corporate structure, including its incorporation in Nevada and its principal executive offices located at 590 Madison Avenue, New York, NY.

Why It Matters

This filing provides an update on Hoth Therapeutics' corporate and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• November 20, 2024 (date) — Date of Report
• Nevada (jurisdiction) — State of Incorporation
• 590 Madison Ave., 21st Floor New York, New York 10022 (address) — Principal Executive Offices
• (646) 756-2997 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value HOTH The Nasdaq Stock Mar
• $1 million — pproved the Company's purchase of up to $1 million in Bitcoin as a treasury reserve asset.

Filing Documents

• ea0221896-8k_hoth.htm (8-K) — 29KB
• ea022189601ex99-1_hoth.htm (EX-99.1) — 7KB
• 0001213900-24-100368.txt ( ) — 213KB
• hoth-20241120.xsd (EX-101.SCH) — 3KB
• hoth-20241120_lab.xml (EX-101.LAB) — 33KB
• hoth-20241120_pre.xml (EX-101.PRE) — 22KB
• ea0221896-8k_hoth_htm.xml (XML) — 4KB

Risk Factors

Risk Factors The Company is supplementing the risk factors previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023 with the following risk factor: Risks Related to the Company Bitcoin's price has been volatile which may undermine its reliability as a store of value and may have a material adverse effect on the Company's financial condition . Bitcoin's price has been volatile and often experiences sharp price movements due to its speculative nature and diverse sentiments of its global investor base. Regulatory changes may further effect Bitcoin's volatility. For example, in 2021, China's ban on crypto trading and mining led to a significant drop in Bitcoin price. While the Company's board has approved the purchase up to $1 million in Bitcoin as a treasury reserve asset, the volatility associated with Bitcoin may undermine its reliability as a store of value, including its long-term value, which may have a material adverse effect on the Company's financial condition. Cautionary Note Regarding

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this Current Report on Form 8-K include, but are not limited to, statements that relate to the Company's potential purchase of Bitcoin as a treasury reserve asset and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as the Company's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements t

01 Financial

Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1 Press release of Hoth Therapeutics, Inc. dated November 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 20, 2024 Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer -2-

View Full Filing

View this 8-K filing on SEC EDGAR